Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
To evaluate the efficacy, safety and tolerability of various doses and durations of linezolid plus bedaquiline and pretomanid after 26 weeks of treatment in participants with either pulmonary XDR-TB, pre-XDR-TB, or treatment intolerant or non-responsive MDR-TB.
Epistemonikos ID: b18deea10b6713222a681761d3ec03c2408169a6
First added on: May 20, 2024